Value of hs-cTnⅠ combined with MR-proADM in the peripheral blood in predicting short-term prognosis of acute myocardial infarction patients
Objective To analyze the value of peripheral blood hypersensitive troponin Ⅰ(hs-cTnⅠ)combined with mid-regional proadrenomedullin(MR-proADM)in predicting short-term prognosis of acute myocardial infarction(AMI)patients.Methods The clinical data of 81 AMI patients admitted to Xi'an Ninth Hospital from March 2022 to February 2023 were retrospectively analyzed.There were 47 males and 34 females,aged 26-79(52.37±8.46)years.The major adverse cardiovascular events(MACE)within 12 months after discharge were statistically analyzed,and the patients were divided into a poor prognosis group(MACE)and a good prognosis group(non-MACE).The baseline data of the two groups were analyzed,and the factors influencing the short-term prognosis of AMI patients were analyzed by logistic regression analysis.The predictive value of serum hs-cTnⅠ and MR-proADM for short-term prognosis of AMI patients was analyzed by receiver operating characteristic curve(ROC).x2 test and independent sample t test were used.Results Among the 81 patients with AMI,27 cases had poor prognosis and 54 cases had good prognosis.Compared with the good prognosis group,the rates of Killip grade Ⅲ,chest pain,and three-vessel coronary artery lesions and the levels of hs-cTnⅠ and MR-proADM in the poor prognosis group were higher(all P＜0.05).Multivariate logistic regression analysis found that Killip grade Ⅲ[OR=4.375(1.495,12.801)],chest pain[OR=3.7 69(1.400,10.151)],three-vessel coronary artery lesions[OR=3.950(1.297,12.030)],hs-cTnⅠ[OR=4.049(1.414,11.591)],and MR-proADM[OR=1.161(1.082,1.246)]were independent risk factors for poor short-term prognosis in AMI patients(all P＜0.05).According to the ROC,the area under the curve(AUC)of hs-cTnⅠ combined with MR-proADM in predicting poor short-term prognosis of AMI patients was 0.903,which was significantly higher than that of hs-cTnⅠ and MR-proADM(both P＜0.05).Conclusion hs-cTnⅠ combined with MR-proADM in the peripheral blood can predict the short-term prognosis of AMI patients.
万方数据
